Home Newsfeeds SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $34

SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $34

SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $30 to $34.

byBenzinga Newsdesk

December 7, 2022

1 minute read

SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $30 to $34.

Zoom’s Pace of Innovation Is Good, But Analysts Hold Reservations Due To Competitive Landscape

By Anusuya Lahiri

October 5, 3:37 PM

Needham analyst Ryan Koontz reiterated a Hold rating on Zoom Video Communications, Inc (NASDAQ:

MSFT

Citigroup Maintains Neutral on Sweetgreen, Raises Price Target to $19

By Benzinga Newsdesk

November 1, 10:04 AM

Citigroup analyst Jon Tower maintains Sweetgreen (NYSE:SG) with a Neutral and raises the price target from $15 to $19.

Did Someone Know Elon Musk Was Buying Twitter Again? Options Flow May Point To An Answer

By Chris Katje

October 6, 11:13 AM

Elon Musk is, once again, offering to acquire Twitter Inc (NYSE: TWTR). While the announcement sent shares of the social media platform soaring, some investors may have profited early from the news.

MANU

Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge

By Lisa Levin

October 24, 12:23 PM

U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday.

AGTC

SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $34

Related Posts

Zoom’s Pace of Innovation Is Good, But Analysts Hold Reservations Due To Competitive Landscape

Citigroup Maintains Neutral on Sweetgreen, Raises Price Target to $19

Did Someone Know Elon Musk Was Buying Twitter Again? Options Flow May Point To An Answer

Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge